Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Biostage, Inc. (BSTG)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
5.340.00 (0.00%)
At close: 03:04PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.34
Open4.70
Bid0.00 x 0
Ask0.00 x 0
Day's Range5.34 - 5.34
52 Week Range1.11 - 6.80
Volume916
Avg. Volume2,170
Market Cap57.076M
Beta (5Y Monthly)-0.34
PE Ratio (TTM)N/A
EPS (TTM)-0.33
Earnings DateNov 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    Biostage Reports Q1 2022 Financial Results and Corporate Highlights

    Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating esophageal cancer (conducted at the Mayo Clinic and published last August) and FDA approval to commence a clinical trial of the Biostage Esophageal Implant, or BEI, for severe esophageal disease including cancer, today announced its financial results for the three months ended March 31, 2022, and highlighted recent events.

  • PR Newswire

    Biostage Announces $5.1 Million Financing to Advance Clinical Trial

    Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience in treating esophageal cancer (conducted at the Mayo Clinic and published last August) and FDA approval to commence a clinical trial of the Biostage Esophageal Implant for severe esophageal disease including cancer, today announced that it has raised approximately $5.1 million from new and existing investors in a private placement of its shares. Additional de

  • PR Newswire

    Biostage Schedules Conference Call and Webcast for Q1 2022 Results

    Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating esophageal cancer (conducted at the Mayo Clinic and published last August) and FDA approval to commence a clinical trial of the Biostage Esophageal Implant for severe esophageal disease including cancer, today announced that it will release Q1 2022 financial results on May. 16th and host a conference call May. 17th to discuss financial results f

Advertisement
Advertisement